Key result
Olanzapine was the most probable cause of neuroleptic malignant syndrome in 16 of 26 reviewed cases, with prior NMS identified as an important risk factor.
Why the study?
What are the clinical characteristics of olanzapine-induced neuroleptic malignant syndrome?
Population
26 cases of neuroleptic malignant syndrome associated with olanzapine
Design
Systematic_review
Authors
Loading...
Olanzapine is a potential cause of neuroleptic malignant syndrome, which typically presents with rigidity and is more likely in patients with a history of prior NMS.
Systematic Review (n=26)
What are the clinical characteristics of olanzapine-induced neuroleptic malignant syndrome?
Olanzapine is a potential cause of neuroleptic malignant syndrome, which typically presents with rigidity and is more likely in patients with a history of prior NMS.
Kogoj et al. (2003) conducted a systematic review in Neuroleptic malignant syndrome (n=26). Olanzapine was evaluated on Probability of olanzapine-induced NMS and clinical presentation. Olanzapine was the most probable cause of neuroleptic malignant syndrome in 16 of 26 reviewed cases, with prior NMS identified as an important risk factor.
Synapse has enriched one closely related paper. Consider it for comparative context: